

## Relatlimab

Cat. No.:	HY-P99156
CAS No.:	1673516-98-7
Target:	LAG-3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC <sub>50</sub> value of 0.67 nM and LAG-3/FGL1 interaction with an IC <sub>50</sub> value of 0.019 nM. Relatlimab can be used in research of cancer <sup>[1]</sup> .
<b>In Vitro</b>	Relatlimab (BMS-986016; 0.001-100 nM) recognizes native LAG-3 and binds to primary activated human and cynomolgus CD4+ T cells with EC <sub>50</sub> values of 0.11 nM and 29.11 nM, respectively <sup>[1]</sup> . ?Relatlimab (0.001-10000 nM; T cells (3A9-hLAG-3)) enhances peptide responsiveness of T-cell hybridoma 3A9-hLAG-3 and reversals LAG-3-mediated inhibition of T-cell hybridoma 3A9-hLAG-3 with an IC <sub>50</sub> value of 1.05 nM <sup>[1]</sup> . ?Relatlimab (0.001-10000 nM; primary T cells) enhances activation of superantigen-stimulated human PBMC cultures and enhances IL-2 secretion <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Thudium K, et, al. Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab. Cancer Immunol Res. 2022 Aug 18;CIR-22-0057.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA